Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Asahi Kasei Closes Tender Offer for Calliditas, Enriches Renal Franchise
September 4, 2024
- Stella Pharma, NCC, Sumitomo Heavy Industries Tie Up in BNCT Basket Trial
September 4, 2024
- Aculys Pharma Files Diazepam Nasal Spray in Japan
September 3, 2024
- PET Agent Vizamyl Approved for Use in Patients on Anti-Aβ Therapy
September 3, 2024
- Nichi-Iko to Finally Roll Out Halaven AG Nearly 4 Years after Approval
September 3, 2024
- Ex-Sanofi Exec John Pulvar Tapped as New CEO of Ferring Japan
September 3, 2024
- BMS Aspires to Double Japan Sales over Next Decade with 5 Growth Drivers
September 3, 2024
- RaQualia’s Acid Reducer Tegoprazan Approved in Colombia
September 3, 2024
- Janssen Offloads Nizoral Cream to Teikoku Seiyaku
September 3, 2024
- Susmed Seeks Partial Change of Approval for Insomnia App towards Coverage
September 3, 2024
- Mounjaro Wins Podium in July GP Rep Promotion Rankings: Intage
September 3, 2024
- Takeda Shooting for Rail Transport Ratio of 60% in Modal Shift Push
September 2, 2024
- Takeda Pushes Back Shipping Date as Trucker Overtime Cap Hits Logistics
September 2, 2024
- Gilead, Cancer Institute Hospital Form R&D Partnership
September 2, 2024
- Pfizer Japan Seeks Partial Change of Champix’s Approval towards Re-Supply
September 2, 2024
- Pfizer Rolls Out Prevenar 20 in Japan, Pediatric NIP Set to Start October
September 2, 2024
- Mochida, Meiji Expand Epadel Sales Collab to ASEAN, Taiwan
September 2, 2024
- Humira Filed for nr-axSpA in Japan Based on Public Knowledge: AbbVie
September 2, 2024
- UCB’s Anti-Epileptic Drug Briviact Now Available in Japan
September 2, 2024
- Majority of PNH Patients Expected to Switch to Novartis’ Fabhalta: Expert
August 30, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…